Financhill is a comprehensive financial analysis platform that provides stock analysis, market data, investment tools, and educational resources to help investors make informed decisions.

How do I get started with Financhill?

You can start by creating a free account, exploring our stock analysis tools, setting up a watchlist, or trying our 7-day trial for full access to all premium features.

What features does Financhill offer?

Financhill offers stock analysis, technical charts, fundamental data, earnings information, dividend tracking, portfolio management, market screening tools, and educational resources.

What are 10K annual reports?

10K reports are comprehensive annual reports filed by public companies with the SEC, containing detailed financial statements, business operations, risk factors, and management discussion.

How often are annual reports updated?

Annual reports are typically filed once per year, usually within 60-90 days after the company's fiscal year end. We update our database as soon as new reports become available.

How do I analyze UTHR stock?

Use our comprehensive analysis tools including technical charts, fundamental metrics, earnings data, and Stock Score to evaluate UTHR investment potential.

What is UTHR stock price today?

Get real-time UTHR stock price, historical data, and price charts on Financhill. Track UTHR performance with our advanced analysis tools.

Is UTHR a good investment?

Evaluate UTHR investment potential using our Stock Score, fundamental analysis, technical indicators, and earnings data. Consider your risk tolerance and investment goals.

How to buy UTHR stock?

To buy UTHR stock, open a brokerage account, research the company using our analysis tools, and place your order through your broker. Always do your own research before investing.

What is the market cap of UTHR?

View detailed market capitalization data and company valuation metrics for UTHR on our comprehensive analysis page.

What is the P/E ratio of UTHR?

Use our fundamental analysis tools to view UTHR P/E ratio and compare valuation metrics with industry peers.

What are UTHR earnings?

View UTHR earnings data, quarterly results, revenue growth, and profit margins on our comprehensive earnings analysis page. Track earnings trends and analyst estimates.

Back

United Therapeutics Corp. 10K Form

Buy

UTHR
United Therapeutics Corp.

Last Price:

$504.10

Seasonality Move:

3.01%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2024-05-01	10Q	UTHR/United Therapeutics Corp. Quarterly
2023-11-01	10Q	UTHR/United Therapeutics Corp. Quarterly
2023-08-02	10Q	UTHR/United Therapeutics Corp. Quarterly
2023-05-03	10Q	UTHR/United Therapeutics Corp. Quarterly
2022-11-02	10Q	UTHR/United Therapeutics Corp. Quarterly
2022-08-03	10Q	UTHR/United Therapeutics Corp. Quarterly

Receive UTHR News And Ratings

See the #1 stock for the next 7 days that we like better than UTHR

UTHR Financial Statistics

Sales & Book Value

Annual Sales:	$3.2B
Cash Flow:	$173.3M
Price / Cash Flow:	23.3
Annual Sales:	$162.60
Price / Book:	3.06

Profitability

EPS (TTM):	27.90010
Net Income (TTM):	$1.3B
Gross Margin:	$2.8B
Return on Equity:	19.56%
Return on Assets:	17.37%

United Therapeutics Corp. Earnings Forecast

Key United Therapeutics Corp. Financial Ratios

The Gross Profit Margin over the past 28 years for UTHR is 87.92%.
The Selling, General & Administrative Expenses for UTHR have been equal to 0.00% of Gross Profit Margin.
The Research & Development expenses have been 17.28% of Revenue.
The Interest Expense is 1.46% of Operating Income.
The Net Earning history of UTHR is 41.94% of Total Revenues.
Per Share Earnings over the last 28 years have been positive in 19 years.

United Therapeutics Corp. Stock Price Chart

Industry, Sector and Symbol

Stock Exchange:	NASDAQ
Industry:	Biotechnology
Sector:	Health Care
Current Symbol:	UTHR
CUSIP:	91307C
Website:	unither.com

Debt

Debt-to-Equity Ratio:	0
Current Ratio:	6.6
Quick Ratio:	5.83

Price-to-Earnings

Trailing P/E Ratio:	18.08
Forward P/E Ratio:	15.78

UTHR Technical Analysis vs Fundamental Analysis

Buy

United Therapeutics Corp. (UTHR) is a Buy

Is United Therapeutics Corp. a Buy or a Sell?

United Therapeutics Corp. stock is rated a Buy

The current United Therapeutics Corp. [UTHR] share price is $503.90. The Score for UTHR is 51, which is 2% above its historic median score of 50, and infers lower risk than normal.